Evidence map›Paper›PMID 42315018›Full record

ArticleKidney international2026

Quantitative serological detection of NELL1 autoantibodies in membranous nephropathy.

Peter D Burbelo, Lilian Howard, Tiffany N Caza, Dorin-Bogdan Borza, Richard W Childs, John A Chiorini, Meryl Waldman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Peter D BurbeloAdeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA. Electronic address: Burbelop@nidcr.nih.gov.
Lilian HowardKidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Tiffany N CazaArkana Laboratories, Little Rock, Arkansas, USA.
Dorin-Bogdan BorzaDepartment of Microbiology, Immunology and Physiology, Meharry Medical College, Nashville, Tennessee, USA.
Richard W ChildsCellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
John A ChioriniAdeno-Associated Virus Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland, USA.
Meryl WaldmanKidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Funding

Adeno-associated Virus Biology And Utilization For Gene TransferZ01DE000695 · NIDCR · NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH · PI CHIORINI, JOHN A · 2000 to 2008
$3.4M
Studies of Immunologically-Mediated Kidney DiseasesZIADK075179 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI WALDMAN, MERYL · 2024 to 2025
$1.2M
Intramural NIH HHS Z01 DE000695Intramural NIH HHS Z99 DE999999Intramural NIH HHS ZIA DK075179
6 · The paper itself

Abstract

introductionMembranous nephropathy (MN) comprises distinct subtypes driven by autoantibodies targeting podocyte-associated proteins, one of which is neural EGFL-like 1 (NELL1). Currently, the diagnosis of NELL1-associated MN relies mainly on mass spectrometry or immunostaining of kidney biopsies. Serologic testing for anti-NELL1 antibodies is not yet commercially available, but research assays including Western blotting, indirect immunofluorescence, and ELISA have recently been developed. However, these are currently performed only in research settings, and ELISA may not be sufficiently specific for primary diagnostic purposes. High-throughput immunoassays are needed for the diagnosis and monitoring of NELL1 autoantibody-positive patients with MN.

methodsHere, we developed a luciferase immunoprecipitation systems (LIPS) immunoassay to detect circulating NELL1 autoantibodies. After identifying the optimal antigenic region of NELL1, we evaluated the assay's diagnostic performance using serum samples derived from a biopsy-proven NELL1

resultsInitial assay development using known NELL1 positive sera demonstrated an N-terminal fragment of NELL1 protein (amino acids 1-550) fused to Gaussia luciferase yielded superior diagnostic performance compared with full-length NELL1 (810 amino acids). In a validation cohort consisting of sera from 20 biopsy-proven NELL1-positive and 20 PLA2R

conclusionsOur NELL1 LIPS assay provides a noninvasive tool for diagnosing NELL1-associated MN, characterizing clinical subsets, and monitoring therapeutic response.

Indexed as

AutoantibodiesCalcium-Binding ProteinsGlomerulonephritis, MembranousNerve Tissue ProteinsAdultBiomarkersEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoprecipitationMaleMiddle AgedNucleobindinsPredictive Value of TestsReceptors, Phospholipase A2Reproducibility of ResultsAutoantibodiesBiomarkersCalcium-Binding ProteinsNELL1 protein, humanNerve Tissue ProteinsNucleobindinsPLA2R1 protein, humanReceptors, Phospholipase A2autoantibodiesmembranous nephropathynephrotic syndrome

Identifiers

PMID42315018
PMCPMC13492885

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.